Glucotrack CEO gets 42 shares; post-transaction holding 339

Glucotrack, Inc. (GCTK) reported an insider transaction on Form 4.

Rhea-AI Filing Summary

Glucotrack, Inc. (GCTK) reported an insider transaction on Form 4. The company’s Chief Executive Officer and director received 42 shares of common stock on 03/25/2025, issued upon achievement of a milestone under an October 7, 2022 Intellectual Property Purchase Agreement. The transaction is coded J (other).

Following this issuance, the reporting person beneficially owns 339 shares, held directly. The company notes that all figures reflect reverse stock splits implemented on 05/17/2024, 02/25/2025, and 06/13/2025.

Insider Trade Summary

Other: 42 shares

Other 1 txn

Insider Goode Paul

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Other	Common Stock, par value $0.001 per share	42	$0.00	$0.00

Holdings After Transaction: Common Stock, par value $0.001 per share — 339 shares (Direct)

Footnotes (1)

1. F1. On October 7, 2022, the reporting person entered into an into Intellectual Property Purchase Agreement (the "IP Purchase Agreement") with Glucotrack, Inc. (the "Issuer"), pursuant to which the reporting person is entitled to certain specified milestone payments, payable in common stock, par value $0.001 per share, of the Issuer (the "Common Stock"), as set forth in the IP Purchase Agreement. Upon the achievement of the third milestone contemplated by the IP Purchase Agreement, the reporting person was issued 42 shares of Common Stock, pursuant to the terms of the IP Purchase Agreement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/07/2025 - 07:26 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Goode Paul

(Last) (First) (Middle)

C/O GLUCOTRACK, INC.

301 RTE. 17 NORTH, SUITE 800

(Street)

RUTHERFORD NJ 07070

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Glucotrack, Inc. [ GCTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.001 per share	03/25/2025		J(1)		42	A	(1)	339	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On October 7, 2022, the reporting person entered into an into Intellectual Property Purchase Agreement (the "IP Purchase Agreement") with Glucotrack, Inc. (the "Issuer"), pursuant to which the reporting person is entitled to certain specified milestone payments, payable in common stock, par value $0.001 per share, of the Issuer (the "Common Stock"), as set forth in the IP Purchase Agreement. Upon the achievement of the third milestone contemplated by the IP Purchase Agreement, the reporting person was issued 42 shares of Common Stock, pursuant to the terms of the IP Purchase Agreement.

Remarks:

On May 17, 2024, a 1-for-5 reverse stock split of the Issuer's Common Stock was implemented (the "2024 Reverse Split"). On February 25, 2025, a 1-for-20 reverse stock split of the Common Stock was implemented (the "February 2025 Reverse Split"), and on June 13, 2025, a 1-for-60 reverse stock split of the Common Stock was implemented (the "June 2025 Reverse Stock Split", and together with the 2024 Reverse Split and the February 2025 Reverse Stock Split, the "Reverse Stock Splits"). All figures presented in this Form 4 reflect the Reverse Stock Splits.

	/s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact	10/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.